Kailera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing advanced therapies for obesity treatment. The company is advancing a diverse portfolio of injectable and oral therapies, including its lead candidate, KAI-9531, an injectable dual GLP-1/GIP receptor agonist. Kailera aims to deliver next-generation weight management solutions that empower individuals to improve their health and quality of life. Based in Waltham, MA, and San Diego, CA, Kailera is focused on addressing the global obesity challenge through innovative therapeutic approaches.
